Skymount Medical accelerates drug discovery through its platform DeepDrug which uses AI-driven methods to significantly reduce long R&D cycles. DeepDrug utilizes computational techniques to streamline drug discovery with AI algorithms analyzing vast chemical spaces, and identifying potential drug candidates rapidly. Besides this, the AI analyzes protein-protein interactions to map known antiviral peptides to cell mechanisms.